GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78
Authors
Keywords
Prostate, Cancer, Targeting, KDEL, GRP78, Nanoparticle, Paclitaxel
Journal
Targeted Oncology
Volume 8, Issue 4, Pages 225-230
Publisher
Springer Nature
Online
2012-10-22
DOI
10.1007/s11523-012-0234-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GRP78 Protein Expression in Ovarian Cancer Patients and Perspectives for a Drug-Targeting Approach
- (2012) Florence Delie et al. Journal of Oncology
- Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells
- (2011) Marie Cohen et al. CANCER LETTERS
- Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells
- (2011) Janeen H. Trembley et al. CANCER LETTERS
- A Critical Role for GRP78/BiP in the Tumor Microenvironment for Neovascularization during Tumor Growth and Metastasis
- (2011) D. Dong et al. CANCER RESEARCH
- Active-Targeted Nanotherapy Strategies for Prostate Cancer
- (2011) M. Katsogiannou et al. CURRENT CANCER DRUG TARGETS
- The formulation of aptamer-coated paclitaxel–polylactide nanoconjugates and their targeting to cancer cells
- (2010) Rong Tong et al. BIOMATERIALS
- Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells
- (2010) Uma K. Misra et al. CANCER BIOLOGY & THERAPY
- Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78
- (2010) Yasufumi Katanasaka et al. INTERNATIONAL JOURNAL OF CANCER
- Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice
- (2010) A. Cirstoiu-Hapca et al. JOURNAL OF CONTROLLED RELEASE
- Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy
- (2010) Mohamed O. Abdalla et al. JOURNAL OF CONTROLLED RELEASE
- HPMA Copolymer-Aminohexylgeldanamycin Conjugates Targeting Cell Surface Expressed GRP78 in Prostate Cancer
- (2010) Nate Larson et al. PHARMACEUTICAL RESEARCH
- The Tumor Suppressor Par-4 Activates an Extrinsic Pathway for Apoptosis
- (2009) Ravshan Burikhanov et al. CELL
- Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells
- (2009) A. Cirstoiu-Hapca et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis
- (2009) U. K. Misra et al. MOLECULAR CANCER THERAPEUTICS
- Identification of Proteins Associating with Glycosylphosphatidylinositol- Anchored T-Cadherin on the Surface of Vascular Endothelial Cells: Role for Grp78/BiP in T-Cadherin-Dependent Cell Survival
- (2008) M. Philippova et al. MOLECULAR AND CELLULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started